Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Court Rules for Biothera in Patent Infringement Suit
February 6, 2006
1 Min Read
Court Rules for Biothera in Patent Infringement Suit
EAGAN, Minn. The U.S. DistrictCourt, District of Minnesota, in Minneapolis entered a judgment in favor ofBiothera in its patent infringement lawsuit against Nanjing, China-based FenchemEnterprises. The court ordered Fenchem to stop selling its GreenShieldingredient or any other yeast-derived beta-glucan product in the United States. Biothera originally filed the lawsuit in March 2005; similarlawsuits filed against Tromso, Norway-based Biotec Pharmacon ASA and its U.S. distributor Immunocorp regarding the product Immutol® arestill pending.
The court order protects our products and furtherstrengthens our ability to defend against patent infringers, said RichardMueller, president and chief executive officer (CEO) of Biothera(www.biotherapharma.com).
You May Also Like